Cargando…
RNASeq profiling of COVID19‐infected patients identified an EIF2AK2 inhibitor as a potent SARS‐CoV‐2 antiviral
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9627224/ https://www.ncbi.nlm.nih.gov/pubmed/36321336 http://dx.doi.org/10.1002/ctm2.1098 |
| _version_ | 1784822918678577152 |
|---|---|
| author | Jain, Sidharth Rego, Samantha Park, Steven Liu, Yiran Parn, Simone Savsani, Kush Perlin, David S. Dakshanamurthy, Sivanesan |
| author_facet | Jain, Sidharth Rego, Samantha Park, Steven Liu, Yiran Parn, Simone Savsani, Kush Perlin, David S. Dakshanamurthy, Sivanesan |
| author_sort | Jain, Sidharth |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9627224 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | John Wiley and Sons Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-96272242022-11-03 RNASeq profiling of COVID19‐infected patients identified an EIF2AK2 inhibitor as a potent SARS‐CoV‐2 antiviral Jain, Sidharth Rego, Samantha Park, Steven Liu, Yiran Parn, Simone Savsani, Kush Perlin, David S. Dakshanamurthy, Sivanesan Clin Transl Med Letter to the Editor John Wiley and Sons Inc. 2022-11-02 /pmc/articles/PMC9627224/ /pubmed/36321336 http://dx.doi.org/10.1002/ctm2.1098 Text en © 2022 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Letter to the Editor Jain, Sidharth Rego, Samantha Park, Steven Liu, Yiran Parn, Simone Savsani, Kush Perlin, David S. Dakshanamurthy, Sivanesan RNASeq profiling of COVID19‐infected patients identified an EIF2AK2 inhibitor as a potent SARS‐CoV‐2 antiviral |
| title | RNASeq profiling of COVID19‐infected patients identified an EIF2AK2 inhibitor as a potent SARS‐CoV‐2 antiviral |
| title_full | RNASeq profiling of COVID19‐infected patients identified an EIF2AK2 inhibitor as a potent SARS‐CoV‐2 antiviral |
| title_fullStr | RNASeq profiling of COVID19‐infected patients identified an EIF2AK2 inhibitor as a potent SARS‐CoV‐2 antiviral |
| title_full_unstemmed | RNASeq profiling of COVID19‐infected patients identified an EIF2AK2 inhibitor as a potent SARS‐CoV‐2 antiviral |
| title_short | RNASeq profiling of COVID19‐infected patients identified an EIF2AK2 inhibitor as a potent SARS‐CoV‐2 antiviral |
| title_sort | rnaseq profiling of covid19‐infected patients identified an eif2ak2 inhibitor as a potent sars‐cov‐2 antiviral |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9627224/ https://www.ncbi.nlm.nih.gov/pubmed/36321336 http://dx.doi.org/10.1002/ctm2.1098 |
| work_keys_str_mv | AT jainsidharth rnaseqprofilingofcovid19infectedpatientsidentifiedaneif2ak2inhibitorasapotentsarscov2antiviral AT regosamantha rnaseqprofilingofcovid19infectedpatientsidentifiedaneif2ak2inhibitorasapotentsarscov2antiviral AT parksteven rnaseqprofilingofcovid19infectedpatientsidentifiedaneif2ak2inhibitorasapotentsarscov2antiviral AT liuyiran rnaseqprofilingofcovid19infectedpatientsidentifiedaneif2ak2inhibitorasapotentsarscov2antiviral AT parnsimone rnaseqprofilingofcovid19infectedpatientsidentifiedaneif2ak2inhibitorasapotentsarscov2antiviral AT savsanikush rnaseqprofilingofcovid19infectedpatientsidentifiedaneif2ak2inhibitorasapotentsarscov2antiviral AT perlindavids rnaseqprofilingofcovid19infectedpatientsidentifiedaneif2ak2inhibitorasapotentsarscov2antiviral AT dakshanamurthysivanesan rnaseqprofilingofcovid19infectedpatientsidentifiedaneif2ak2inhibitorasapotentsarscov2antiviral |